Ekachai Medical Care Public Company (EKH) Fair Value & Analysis
Healthcare · TH · Market cap 4.0B THB
Fair value as of: Jul 18, 2026
From 16 valuation models · updated 23 days ago
Share price −1.0% over the past month.
Below-average quality, screening 17% undervalued on our models.
What matters now
- A fairly wide model range (4.08 THB to 7.58 THB) leaves room in how you read the outcome.
- Our model range runs from 4.08 THB (bear) to 7.58 THB (bull), base 5.83 THB. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 45/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range 3.73 THB – 7.02 THB · fair‑value band 4.08 THB – 7.58 THB · the 5.00 THB price screens below the 5.83 THB fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Ekachai Medical Care Public Company (EKH) currently trades at 5.00 THB, while our model-based Fair Value estimate is 5.83 THB, implying the stock looks roughly 16.6% undervalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Ekachai Medical Care Public Company generated revenue of 1.3B THB at a net margin of 20.6%. Revenue grew 6.3% year over year. It earns a return on equity of 10.3%. The balance sheet holds a net cash position of 551M THB. Fundamentals as of Jul 18, 2026
Our scenario range runs from 4.08 THB (bear case) to 7.58 THB (bull case); at 5.00 THB, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 17%, EKH screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (5.83 THB) versus Asset-Based (1.99 THB). Highest evidence: Residual Income (76).
Notify me when EKH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Ekachai Medical Care Public Company Limited, together with its subsidiaries, operates Ekachai hospital in Thailand. The company offers various surgeries comprising face and neck lift; forehead augmentation; eyelid and ear correction; nose reshaping; breast lifting, implants, reduction with implants, and lifting without implants; nipple-areolar; preventive …
Full company description
Ekachai Medical Care Public Company Limited, together with its subsidiaries, operates Ekachai hospital in Thailand. The company offers various surgeries comprising face and neck lift; forehead augmentation; eyelid and ear correction; nose reshaping; breast lifting, implants, reduction with implants, and lifting without implants; nipple-areolar; preventive mastectomy; male breast reduction; mastectomy; power assisted and body tite liposuction; lipofilling; body contouring; female genetical cosmetic; and gender reassugnment. It also operates cosmetic surgery; EKI-IVF Fertility and genetic; ophthalmology; obstertrics and gynaecology; pediatrics; orthopedics; general surgery; emergency; health promotion; hemodialysis; dental; physical; pre employment and mobile checkup; internal medicine; aesthetic and dermatology; and child and teen development centers. In addition, the company provides infertility and elderly care centers; and operates psychiatric hospitals, and specialized hospitals for elders. Ekachai Medical Care Public Company Limited was incorporated in 2003 and is based in Mueang Samut Sakhon, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ekachai Medical Care Public Company reported revenue of 1.2B THB in FY2025 versus 1.1B THB in FY2021, a compound +2.0%/yr. Reported net income was 262M THB in FY2025, compounding −6.6%/yr from FY2021.
of which total revenue +12.0 pp · buybacks/dilution −4.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch EKH: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 42/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Ekachai Medical Care Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ekachai Medical Care Public Company (EKH) overvalued or undervalued?
What is the fair value of EKH?
What is the quality score of EKH?
What is the revenue of Ekachai Medical Care Public Company (EKH)?
What is the net profit margin of EKH?
Does Ekachai Medical Care Public Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Ekachai Medical Care Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.